Currently, a variety of cell cycle checkpoint kinase inhibitors are also under research and their anti-tumor effects in combination with PARP inhibitors are evaluated, including inhibition of CHEK1/2, ATM, ATR, and WEE1 in breast cancer [169, 180, 220]. This evidence concerns the gene CHEK1 and neoplasm.